NTLA240816C20000
- 5.92
- 0.000.00%
Intellia Therapeutics Newsroom
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $80
Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
The Past Three Years for Intellia Therapeutics (NASDAQ:NTLA) Investors Has Not Been Profitable
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
Intellia Therapeutics(NTLA.US) Officer Sells US$9,286.65 in Common Stock
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $24 to $73
Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $29 to $95
Intellia Therapeutics: Dulac Recently Served as CFO of Fate Therapeutics >NTLA
Express News | Intellia Therapeutics Inc - Glenn Goddard to Step Down as CFO Effective June 30, 2024
Express News | Intellia Therapeutics Inc - Appoints Edward Dulac as CFO Effective July 22, 2024
Express News | Intellia Therapeutics Announces CFO Transition
Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies